We are speaking at the 3rd GLOBAL XDC INNOVATION CONFERENCE in WuXi (CHINA)!
We are speaking at the 3rd GLOBAL XDC INNOVATION CONFERENCE in WuXi (CHINA) partnering event in WuXi (CHINA) , 10 – 12 Sep. 2024 We look forward to your presence to explore future partnership opportunities. * * * * * Contact: Valsasina Barbara : Barbara.Valsasina@demo111.axxiem.com Lupi Rosita: rosita.lupi@demo111.axxiem.com * * * * * About NMS […]
Nerviano Medical Sciences announces FDA protocol clearance of new IND application for NMS-812, a first-in-class dual inhibitor of PERK/GCN2. Brian Sherer, PhD. appointed to lead and accelerate the development.
NMS-812: A clinical phase potent and selective PERK/GCN2 inhibitor, a potential first-in-class targeting the integrated stress response (ISR) The United States Food and Drug Administration (FDA) has cleared the protocol for new investigational new drug (IND) application for NMS-812, a first-in-class orally bioavailable and highly potent small molecule dual inhibitor of PERK/GCN2. NMS […]
Nerviano Medical Sciences announces strategic portfolio shaping.
NERVIANO, IT and BOSTON, Mass, June 21 , 2024 – Nerviano Medical Sciences S.r.l. (“NMS” or the “Company”), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, […]
Nerviano Medical Sciences S.r.l. announced new Board of Directors and Statutory Auditors
NERVIANO, 28, May 2024_Nerviano Medical Sciences S.r.l. (NMS), a wholly owned subsidiary of NMS Group S.p.A, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced, following the shareholder resolution dated 13 May 2024, changes to the Board of Directors and Statutory Auditors of the holding company […]
Dr. Frank Narjes Appointed as Head of Medicinal Chemistry and Drug Design, Elevating Innovation at Nerviano Medical Sciences S.r.l.
NERVIANO, IT and BOSTON, Mass, May 13, 2024 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, welcomes Dr. Narjes to […]
Nerviano Medical Sciences S.r.l. presents data on MPS1 inhibitor NMS-153 and on ADC platform at the AACR annual meeting 2024.
Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud of its participation to the American Association of Cancer Research annual meeting (AACR 2024) which took place in San Diego from April 5th to April 10th. NMS […]
Nerviano Medical Sciences establishes its Scientific Advisory Board
Nerviano, IT and Boston, Mass, 26 March, 2024 – Nerviano Medical Sciences S.r.l. (NMS), and Nerviano Medical Sciences, Inc. (NMS-US), a wholly owned subsidiary of NMS S.r.l., focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced the formation of their Scientific Advisory Board (SAB), with the […]
Nerviano Medical Sciences S.r.l. to present data on its platform of payload linkers for ADC conjugation at the World ADC Summit 2024 in London, UK (March 12th-15th, 2024)
Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud to announce its participation to the World ADC 2024 summit that will be held in London, UK (World ADC Europe) from March 12th to March 15th, 2024, with […]
Nerviano Medical Sciences received European Medicines Agency (EMA) Orphan Drug Designation for its next-generation FLT3 inhibitor NMS-03592088 for treatment of Acute Myeloid Leukemia
NERVIANO, IT and BOSTON, Mass, 4 March, 2024 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc. (NMS-US), a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced that European […]
New European Patent Office study: NMS S.r.l. top applicant in Italy during the 2002-2021 period
New European Patent Office study: NMS srl top applicant in Italy during the 2002-2021 period Nerviano, 1 February 2024 The new study “Patents and Innovation against Cancer”, just released today by the European Patent Office (EPO), reports Italy among top European nations in innovation to fight cancer. In the past 20 years close to 2 […]
